DrugPatentWatch Database Preview

Par Pharm Company Profile

PAR PHARM has two hundred and eleven approved drugs.

There is one US patent protecting PAR PHARM drugs. There are fourteen tentative approvals on PAR PHARM drugs.

There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and twenty-two supplementary protection certificates in twelve countries.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Par Pharm	RISPERIDONE	risperidone	TABLET, ORALLY DISINTEGRATING;ORAL	077494-002	Apr 30, 2009	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Par Pharm	FENOPROFEN CALCIUM	fenoprofen calcium	TABLET;ORAL	072429-001	Aug 17, 1988		DISCN	No	No		➤ Sign Up				➤ Sign Up
Par Pharm	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	078381-005	Jul 29, 2010	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Par Pharm	AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	201087-005	Jun 1, 2015	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Par Pharm	CAPOTEN	captopril	TABLET;ORAL	018343-005	Jan 17, 1985	5,238,924	➤ Sign Up
Par Pharm	CAPOTEN	captopril	TABLET;ORAL	018343-002	Approved Prior to Jan 1, 1982	4,105,776	➤ Sign Up
Par Pharm	CAPOTEN	captopril	TABLET;ORAL	018343-004	Jun 13, 1995	5,238,924	➤ Sign Up
Par Pharm	CAPOTEN	captopril	TABLET;ORAL	018343-002	Approved Prior to Jan 1, 1982	5,238,924	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	10 mg and 20 mg	➤ Subscribe	2008-02-29
➤ Subscribe	Nasal Spray	500 mcg/spray	➤ Subscribe	2017-04-28

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
15/009	Ireland	➤ Sign Up	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
2012017,C1920764	Lithuania	➤ Sign Up	PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
C/GB02/042	United Kingdom	➤ Sign Up	PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
14/032	Ireland	➤ Sign Up	PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.